Compare · CNTN vs NVO
CNTN vs NVO
Side-by-side comparison of Canton Strategic Holdings Inc. (CNTN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 928.2x CNTN ($205.9M).
- Over the past year, CNTN is up 81.3% and NVO is down 45.0% - CNTN leads by 126.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for CNTN).
- NVO has more recent analyst coverage (25 ratings vs 0 for CNTN).
- Company
- Canton Strategic Holdings Inc.
- Novo Nordisk A/S
- Price
- $3.00+1.69%
- $43.31+1.23%
- Market cap
- $205.9M
- $191.15B
- 1M return
- -8.54%
- -7.90%
- 1Y return
- +81.27%
- -45.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 1
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNTN
- Director Stetz Gary S. sold $343,882 worth of shares (100,351 units at $3.43), decreasing direct ownership by 43% to 134,175 units (SEC Form 4)
- SEC Form 10-Q filed by Canton Strategic Holdings Inc.
- Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Canton Strategic Holdings Inc.
- Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update
- SEC Form D filed by Canton Strategic Holdings Inc.
- SEC Form D filed by Canton Strategic Holdings Inc.
- SEC Form 10-K filed by Canton Strategic Holdings Inc.
- Canton Strategic Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care